Olivia Brayer
Stock Analyst at Cantor Fitzgerald
(0.29)
# 4,522
Out of 5,053 analysts
138
Total ratings
31.8%
Success rate
-8.1%
Average return
Main Sectors:
Stocks Rated by Olivia Brayer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OMER Omeros | Maintained: Buy | $22 | $18.88 | +16.53% | 3 | Oct 14, 2026 | |
| CTMX CytomX Therapeutics | Reiterated: Buy | $12 | $2.33 | +416.13% | 6 | Oct 13, 2026 | |
| ALNY Alnylam Pharmaceuticals | Reiterated: Hold | $400 → $325 | $223.82 | +45.21% | 12 | Sep 30, 2026 | |
| UTHR United Therapeutics | Initiated Coverage: Buy | $625 → $700 | $543.40 | +28.82% | 5 | Sep 30, 2026 | |
| MNKD MannKind | Reiterated: Buy | $8 | $3.05 | +162.30% | 6 | Sep 10, 2026 | |
| TENX Tenax Therapeutics | Reiterated: Buy | $35 | $1.60 | +2,087.50% | 4 | Sep 9, 2026 | |
| BMRN BioMarin Pharmaceutical | Reiterated: Buy | $85 → $86 | $54.38 | +58.15% | 19 | Sep 1, 2026 | |
| BRVE Braveheart Bio | Initiated Coverage: Buy | $40 | $19.33 | +106.93% | 1 | Aug 31, 2026 | |
| MIST Milestone Pharmaceuticals | Initiated Coverage: Buy | $3 | $0.7658 | +291.75% | 1 | Aug 20, 2026 | |
| INSM Insmed | Reiterated: Buy | $235 | $96.79 | +142.79% | 5 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $11 | $4.30 | +155.81% | 6 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $4 | $0.9188 | +335.35% | 1 | May 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $4 | $1.76 | +127.27% | 2 | May 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $50 | $20.29 | +146.43% | 1 | Apr 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $9.76 | - | 6 | Mar 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $480 | $485.22 | n/a | 23 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $405 → $340 | $412.84 | n/a | 4 | Feb 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $52 → $55 | $56.67 | n/a | 8 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $70 → $80 | $147.92 | n/a | 8 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $795 → $925 | $753.12 | n/a | 4 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $15 → $10 | $16.36 | n/a | 6 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $50.10 | n/a | 3 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $3 | $3.40 | n/a | 4 | Mar 20, 2023 |
Omeros
Oct 14, 2026
Maintained: Buy
Price Target: $22
Current: $18.88
Upside: +16.53%
CytomX Therapeutics
Oct 13, 2026
Reiterated: Buy
Price Target: $12
Current: $2.33
Upside: +416.13%
Alnylam Pharmaceuticals
Sep 30, 2026
Reiterated: Hold
Price Target: $400 → $325
Current: $223.82
Upside: +45.21%
United Therapeutics
Sep 30, 2026
Initiated Coverage: Buy
Price Target: $625 → $700
Current: $543.40
Upside: +28.82%
MannKind
Sep 10, 2026
Reiterated: Buy
Price Target: $8
Current: $3.05
Upside: +162.30%
Tenax Therapeutics
Sep 9, 2026
Reiterated: Buy
Price Target: $35
Current: $1.60
Upside: +2,087.50%
BioMarin Pharmaceutical
Sep 1, 2026
Reiterated: Buy
Price Target: $85 → $86
Current: $54.38
Upside: +58.15%
Braveheart Bio
Aug 31, 2026
Initiated Coverage: Buy
Price Target: $40
Current: $19.33
Upside: +106.93%
Milestone Pharmaceuticals
Aug 20, 2026
Initiated Coverage: Buy
Price Target: $3
Current: $0.7658
Upside: +291.75%
Insmed
Aug 6, 2026
Reiterated: Buy
Price Target: $235
Current: $96.79
Upside: +142.79%
Aug 6, 2026
Reiterated: Buy
Price Target: $11
Current: $4.30
Upside: +155.81%
May 21, 2026
Initiated Coverage: Buy
Price Target: $4
Current: $0.9188
Upside: +335.35%
May 18, 2026
Reiterated: Buy
Price Target: $4
Current: $1.76
Upside: +127.27%
Apr 1, 2026
Initiated Coverage: Buy
Price Target: $50
Current: $20.29
Upside: +146.43%
Mar 20, 2026
Downgraded: Hold
Price Target: n/a
Current: $9.76
Upside: -
Feb 11, 2025
Reiterated: Buy
Price Target: $480
Current: $485.22
Upside: n/a
Feb 5, 2025
Reiterated: Buy
Price Target: $405 → $340
Current: $412.84
Upside: n/a
Feb 4, 2025
Reiterated: Hold
Price Target: $52 → $55
Current: $56.67
Upside: n/a
Nov 6, 2024
Reiterated: Hold
Price Target: $70 → $80
Current: $147.92
Upside: n/a
Apr 17, 2024
Reiterated: Hold
Price Target: $795 → $925
Current: $753.12
Upside: n/a
Feb 23, 2024
Reiterated: Buy
Price Target: $15 → $10
Current: $16.36
Upside: n/a
Oct 17, 2023
Downgraded: Hold
Price Target: n/a
Current: $50.10
Upside: n/a
Mar 20, 2023
Reiterated: Hold
Price Target: $3
Current: $3.40
Upside: n/a